Approval Scope and Company

The European Union approved Bristol Myers Squibb (BMY)'s Onureg (oral azacitidine) for acute myeloid leukemia (AML) maintenance therapy on June 17, 2021. The indication is for adult patients who achieve complete remission (CR) or incomplete blood count recovery complete remission (CRi) after induction therapy but are not receiving hematopoietic stem cell transplantation (HSCT). The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on April 22 of the same year, and this decision made Onureg an approved therapeutic available across Europe.

Drug and Mechanism of Action

Onureg's generic name is azacitidine, a hypomethylating agent that incorporates into DNA and RNA. The key molecular target is DNA methyltransferase (DNMT), which the drug depletes to reduce abnormal DNA methylation, restoring tumor suppressor gene expression and hematopoietic cell differentiation. The oral formulation CC-486 is not bioequivalent to the injectable azacitidine, and this distinction is important in prescribing and pricing strategies.

Clinical Basis

The Phase 3 QUAZAR AML-001 study (NCT01757535), which served as the basis for approval, randomized 472 patients aged 55 years and older to Onureg or placebo. The median overall survival was 24.7 months versus 14.8 months, and the median relapse-free survival was 10.2 months versus 4.8 months, both with p<0.001. Grade 3–4 neutropenia was 41% versus 24%, and thrombocytopenia was 22% versus 21%. Gastrointestinal adverse events were mostly Grades 1–2, establishing a balance between survival improvement and manageable toxicity that supported the approval rationale.

Competitive Landscape and Market

The current standard of care for post-remission therapy is consolidation chemotherapy and HSCT for eligible patients. In FLT3-mutated patients, Novartis (NVS)'s Rydapt (midostaurin; FLT3/KIT inhibitor) is a competitive maintenance therapy in Europe. In non-intensive upfront therapy, AbbVie (ABBV) and Roche (ROG)'s Venclexta (venetoclax; BCL-2 inhibitor) in combination with injectable azacitidine forms a standard backbone, but Onureg's post-remission indication targets a different treatment phase. The global AML treatment market was estimated at approximately USD 3.5 billion in 2024, and Onureg's differentiation as an oral maintenance therapy for HSCT-ineligible remission patients provides a commercial entry point.

Regulatory and Business Implications

The FDA approved Onureg on September 1, 2020, as a continuous therapy for adults who achieve CR or CRi after intensive induction chemotherapy but cannot complete intensive curative therapy. With EU approval following the U.S. approval, BMS can now leverage the same Phase 3 survival data in major Western markets. Since this is not a separate licensing deal but an asset commercialized in-house by BMS through its acquisition of Celgene, no new upfront payments, milestones, or royalties are associated with this event.